Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made materially false and misleading statements regarding its Phase III Fianlimab-Libtayo study, claiming its preliminary statistical assumptions were flawed and the study was unlikely to achieve statistical significance. Investors who suffered losses are encouraged to join the case, with a lead plaintiff deadline of September 14, 2026.
This article provides a detailed financial overview of Whitehawk Therapeutics, Inc. (WHWK), focusing on its revenue breakdown, institutional holdings, insider trading activity, and analyst ratings. It highlights the absence of specific revenue segment or geography data for WHWK. The company is described as an oncology therapeutics firm developing antibody-drug conjugate candidates for cancer treatment.
Eupraxia Pharmaceuticals Inc. (TSE:EPRX) Independent Director John Montalbano recently purchased CA$207k worth of stock at CA$9.42 per share, increasing his holding by 1.4%. This follows a larger purchase by Independent Director Joseph Freedman last year for CA$2.7m at CA$9.59 per share, indicating insider confidence despite the company not being profitable in the last twelve months. Insiders collectively own 16% of the company's shares, valued at approximately CA$95m.
Regeneron Pharmaceuticals recently received FDA approval for Pasatru, a first-in-class treatment for the ultra-rare disease fibrodysplasia ossificans progressiva (FOP). While this approval diversifies Regeneron's revenue in a niche area, the company's investment narrative continues to heavily rely on the performance of its existing key franchises, EYLEA and Dupixent, which face ongoing pricing and competitive pressures. The article suggests that while Pasatru is a positive development, it doesn't fundamentally shift the near-term investment focus away from EYLEA HD execution and the overall risk of concentrated exposure to its main drugs.
Regeneron Pharmaceuticals recently received FDA approval for Pasatru, a first-in-class drug for the ultra-rare disease fibrodysplasia ossificans progressiva (FOP). While this approval diversifies Regeneron's revenue in a niche area, the company's investment narrative still heavily relies on the performance and pricing of its core franchises, EYLEA HD and Dupixent. The approval of Pasatru helps solidify the company's expansion into new biologics, yet the ongoing risk of competition and pricing pressure on its main drugs remains a key concern for investors.
GQG Partners LLC recently acquired 96,264 shares of Bristol Myers Squibb Company, valued at approximately $5.55 million, during the second quarter. This move is part of broader institutional interest, with several other investment firms also adjusting their stakes in the biopharmaceutical company. Bristol Myers Squibb reported strong quarterly earnings and revenue, and analysts predict continued growth, despite facing generic competition for some legacy products.
